39213-22-4

Basic information

• Product Name: 3,5-BIS(TRIFLUOROMETHYL)BENZENESULFONAMIDE
• Synonyms: 3,5-BIS(TRIFLUOROMETHYL)BENZENESULFONAMIDE;3,5-BIS(TRIFLUOROMETHYL)BENZENE SULPHONAMIDE;BUTTPARK 44\03-72
• CAS NO: 39213-22-4
• Molecular Formula: C₈H₅F₆NO₂S
• Molecular Weight: 293.19
• Mol File: 39213-22-4.mol

Chemical Properties

• Melting Point: 180-182°C
• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3,5-BIS(TRIFLUOROMETHYL)BENZENESULFONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-BIS(TRIFLUOROMETHYL)BENZENESULFONAMIDE(39213-22-4)
• EPA Substance Registry System: 3,5-BIS(TRIFLUOROMETHYL)BENZENESULFONAMIDE(39213-22-4)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 39213-22-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
TFBSA is utilized as a reagent in organic synthesis, leveraging its electron-withdrawing properties to facilitate various chemical reactions and the formation of desired products.
Used in Pharmaceutical Production:
In the pharmaceutical industry, TFBSA serves as a building block for the production of drugs, contributing to the development of new medicinal compounds due to its unique chemical characteristics.
Used in Agrochemical Production:
TFBSA is also employed in the creation of agrochemicals, playing a crucial role in the synthesis of compounds that are used to enhance crop protection and yield.
Used in Coordination Chemistry:
TFBSA functions as a ligand in coordination chemistry, participating in the formation of coordination complexes that have applications in catalysis, materials science, and other areas.
Used in Peptide Synthesis:
As a protecting group in peptide synthesis, TFBSA is instrumental in the synthesis of peptides, ensuring the correct formation of peptide bonds and protecting specific functional groups during the reaction process.

Upstream product

• 39234-86-1 3,5-bis(trifluoromethyl)benzenesulfonyl chloride 
• 7440-44-0 pyrographite 

Downstream Products

• 512818-39-2 4-(3,5-bis-trifluoromethyl-benzenesulfonylaminocarbonyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 512820-46-1 10-(3,5-bis-trifluoromethyl-benzenesulfonylaminocarbonyl)-8-aza-bicyclo[4.3.1]decane-8-carboxylic acid tert-butyl ester 
• 512820-66-5 2-{4-[2-(3,5-bis-trifluoromethyl-benzenesulfonylamino)-2-oxo-ethyl]-piperidin-1-yl}-4-trifluoromethyl-benzamide 
• 512821-99-7 1-[2-(3,5-bis-trifluoromethyl-benzenesulfonylamino)-1-(4-chloro-phenyl)-2-oxo-ethyl]-piperidine-4-carboxylic acid cyclohexylamide 
• 1176325-58-8 C₁₇H₁₄F₆INO₂S 
• 1610050-47-9 C₃₆H₃₁F₆NO₂P₂S 
• 1610050-45-7 C₃₂H₂₃F₆NO₂P₂S 
• 1338799-21-5 (S)-N-(3,5-bis(trifluoromethyl)phenylsulfonyl)-pyrrolidine-2-carboxamide 
• 1287189-58-5 N₁-(3,5-bis(trifluoromethyl)phenyl)-N₃-(3,5-bis(trifluoromethyl)phenylsulfonyl)benzene-1,3-dicarboxamide 
• 1165944-26-2 (E)-N-(3-cyclohexylallyl)-3,5-bis(trifluoromethyl)benzenesulfonamide 
• 1165944-33-1 N-((2E,5E)-hepta-2,5-dienyl)-3,5-bis(trifluoromethyl)benzenesulfonamide 

Relevant articles and documents

A recyclable and highly stereoselective multi-fluorous proline catalyst for asymmetric aldol reactions

A recyclable fluorous proline catalyst with high stereoselectivity that functions as a catalyst for asymmetric aldol reactions is described. Its high stereoselectivity and facile recovery are achieved by employing a multi-fluorous tag attachment strategy. Although a gradual decrease was observed with respect to the catalytic activity, the catalyst can be separated from the reaction mixture by adsorption onto FluoroFlash and can be reused in that form for a maximum of five times while maintaining a high stereoselectivity.2019 Elsevier Ltd. All rights reserved.

Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays

Crystallographic overlap studies and pharmacophoric analysis indicated that diarylpyrimidine (DAPY)-based HIV-1 NNRTIs showed a similar binding mode and pharmacophoric features as indolylarylsulfones (IASs), another class of potent NNRTIs. Thus, a novel series of DAPY-IAS hybrid derivatives were identified as newer NNRTIs using structure-based molecular hybridization. Some target compounds exhibited moderate activities against HIV-1 IIIB strain, among which the two most potent inhibitors possessed EC50 values of 1.48?μM and 1.61?μM, respectively. They were much potent than the reference drug ddI (EC50?=?76.0?μM) and comparable to 3TC (EC50?=?2.54?μM). Compound 7a also exhibited the favorable selectivity index (SI?=?80). Preliminary structure-activity relationships (SARs), structure-cytotoxicity relationships, molecular modeling studies, and in silico calculation of physicochemical properties of these new inhibitors were also discussed.

Synthesis and NMR binding studies towards rational design of a series of electron-withdrawing diamide receptors/organocatalysts

A related series of bisamides have been evaluated for rational correlation between anion complexation and organocatalysis: remarkable enhancement of hydrogen bonding to anions was observed along with significant increases in catalytic activity in the Bayl

Regioselective hydroformylation of sulfonamides using a scaffolding ligand

A highly regloselectlve hydroformylatlon of allyllc sulfonamides has been developed by employing a catalytic directing group. The reaction tolerates a wide range of electronically and sterlcally modified olefins, and only 10% of the scaffolding llgand Is required to effectively control the regloselectlvlty.

ANTI-INFLAMMATORY COMPOUNDS

The use of a steroid sulfatase inhibitor in the preparation of a medicament for the treatment of inflammatory diseases.

COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN

A combination of a steroid sulfatase inhibitor and an ascomycin, which combination is useful as a pharmaceutical.

N-Acyl arylsulfonamides as novel, reversible inhibitors of human steroid sulfatase

Steroid sulfatase (STS) is an attractive target for a range of oestrogen- and androgen-dependent diseases. In search of novel chemotypes of STS inhibitors, we had previously identified nortropinyl-arylsulfonylureas 1; however, while these compounds were good inhibitors of purified STS (lowest Ki = 76 nM), they showed only weak inhibition of STS activity in cells (lowest IC50 around 2 μM). Extended structure-activity relationship studies involving modification of the phenylacetyl side chain and replacement of the nortropine element by simpler scaffolds led to the discovery of N-acyl arylsulfonamides, more specifically N-(Boc-piperidine-4-carbonyl)- benzenesulfonamides, as STS inhibitors, some of which exhibit improved cellular potency (best IC50 = 270 nM).

Synthesis and cytotoxic evaluation of substituted sulfonyl-n- hydroxyguanidine derivatives as potential antitumor agents

A series of sulfonyl-N-hydroxygnanidine derivatives was designed and synthesized for cytotoxic evaluation as potential anticancer agents on the basis of the lead compound LY-181984. Replacement of the ureido moiety of the lead compound with hydrexyguanidine provided a stable cytotoxic agent. The conformation of sulfonyl-N-hydroxyguanidine derivatives, such as N-(4- chlorophenyl-)-N-[(benzo[2,3]thiadiazol-4-yl)sulfonyl]-N-hydroxyguanidine (4g), investigated utilizing HMBC NMR, theoretical calculations, and X-ray crystallography, indicated stacking of the two aromatic rings. The derivatives were evaluated for in vitro cytoxicity against five human tumor cell lines, including HepG2, TSGH 8302, COLO 205, KB, and MOLT-4. The cytotoxic activities of the derived compounds against the human tumor cell lines were equal to or greater than that of the lead compound. N-(4- Chlorophenyl)-N'-[[3,5-dichloro-4-(4-nitrophenoxy)phenyl]sulfonyl].N- hydroxyguanidine (4n) and N-(4-chlorophenyl)-N'-[[3,5-dichloro4-(2-chloro-4- nitrophenoxy)phenyl]sulfonyl]-N-hydroxyguanidine (40) exhibited the greatest growth inhibition of solid tumor cell lines. Compound 40 was found to possess antitumor activity against murine K1735/M2 melanoma xenografts.

Substituted benzenesulfonamides as anthelmintics

This invention relates to a novel method for the treatment of parasitic diseases and the compositions used in said treatment. More specifically this invention relates to benzenesulfonamides substituted at the 3, 4, and 5 positions of the benzene ring and to the use of such compounds for the treatment of mature and immature liver fluke infections.